Oxford de citas

Oxford: Update Software Ltd. Disponible en: weebly .. Doscientos cuarenta y ocho citas se relacionaban con el decanoato o el enantato de flufenazina, pero sólo 62 se referían a SDS - Simpson Dyskinesia Scale. New York, Oxford University Press. Lovelock, J. E. La sensación final de frustración generalizada que embargó la culminación de la ... Estilo Oxford de referencias. Primeras citas La primera vez que se cita una fuente, la nota al pie debe proveer detalles bibliográficos completos. Un número superíndice que aparece después del texto relevante se refiere a la nota al pie en la parte inferior de la página. Para citas directas y parafraseo, es necesario proveer un número de página (o referencia equivalente) en la nota al pie. Edward de Vere, 17.º conde de Oxford fue un cortesano, autor teatral, poeta, deportista y mecenas de, por lo menos, dos compañías teatrales Oxford’s Men y Oxford’s Boys,[1] como también de una compañía musical.[2] Fue hijo de John de Vere, decimosexto conde de Oxford, y de Margery Golding. Automatically cite and reference in OSCOLA (Oxford University Standard for Citation of Legal Authorities) style for your bibliography. Easy citation generation. Cree sus citas, listas de referencias y bibliografías de manera automática utilizando los estilos de referencia de la APA, Harvard, ISO 690 o MLA. Oxford English and Spanish Dictionary, Thesaurus, and Spanish to English Translator ... los terroristas tenían en su poder unas hojas de papel con los resultados de vigilancias hechas a vehículos de la policía y una serie de citas, con horas y lugares, ... Generador de citas Oxford para uso fácil y rápido Un generador es un cuadro de campos vacíos que te ayudará a obtener referencias de forma rápida y segura. Para ello, debes tener a la mano la obra que vas a citar e ir llenando los espacios en blanco con los datos pedidos.

Médico da CBF diz que protocolo do futebol pode ter mudanças

2020.08.27 19:41 futebolstats Médico da CBF diz que protocolo do futebol pode ter mudanças

O protocolo de saúde da Confederação Brasileira de Futebol (CBF) para realização dos campeonatos nacionais em meio à pandemia do novo coronavírus (covid-19) deverá sofrer novas alterações com o desenrolar das competições. Segundo o coordenador médico da entidade, Jorge Pagura, um balanço das três primeiras semanas de bola rolando será concluído após as partidas da última quarta-feira (26), que encerraram a quinta rodada da Série A.
“No protocolo, está colocado que ele pode ser modificado a qualquer momento. Então ele vai, sim, realmente sofrer modificações. A gente diz que ele é uma peça viva, é uma foto do momento. Mas ele pode ser modificado, sim, sempre para que melhoremos nosso controle, seja com evidências científicas muito bem pautadas ou até por alguma observação. Estamos avaliando diariamente tudo o que está acontecendo. E o que for necessário fazer para melhorar, nós vamos aprimorar esse protocolo quantas vezes forem necessárias”, afirma Pagura à Agência Brasil.
Os procedimentos já sofreram alterações em relação aos que antecediam os campeonatos. Após a primeira rodada das três divisões nacionais, o atraso na divulgação dos resultados dos exames do Goiás e os vários casos positivos em atletas relacionados para os jogos do fim de semana, levaram a CBF a estender os testes a todos os inscritos pelos clubes e definir novos prazos para envio dos diagnósticos: 24 horas para times mandantes, 12 horas antes da viagem no caso de visitantes. Além disso, por logística, as equipes passaram a poder optar por exames em laboratórios locais, ao invés do Hospital Albert Einstein, de São Paulo, parceiro da confederação.
“Toda vez que é feito um protocolo, ele é pensado no maior número de pessoas que pode atender. À medida que as especificidades aparecem, esse protocolo pode ser adaptado”, avalia Raphael Einsfeld, médico do Esporte e coordenador do curso de Medicina do Centro Universitário São Camilo, à Agência Brasil.
Ele cita o caso em que quatro jogadores do Atlético-GO, que testaram positivo para o novo coronavírus, foram liberados para enfrentar o Flamengo no último dia 12. À Agência Brasil, o clube tinha informado que os atletas vinham sendo acompanhados, cumpriram a quarentena e não possuíam mais potencial de transmissão do vírus. A justificativa foi aceita pela CBF, baseada em uma normativa do Centro de Controle e Prevenção de Doenças (CDC) do governo norte-americano, acatada pela Organização Mundial de Saúde (OMS).
“O CDC puxa uma revisão sistemática [método de pesquisa que reúne as melhores evidências atuais ou disponíveis] de Oxford. Eles descobriram que, após o oitavo dia de infecção, no indivíduo que está assintomático, não há mais replicação viral, apesar de o PCR vir positivo. O PCR pode vir positivo por muito tempo, porque ele detecta o RNA [material genético] do vírus. Não necessariamente o vírus, mas parte dele”, explica Einsfeld.

Controle de casos

Há uma semana, na Câmara dos Deputados, Pagura apresentou dados sobre os testes realizados até aquele momento. Segundo ele, antes de os torneios nacionais começarem, foram aplicados 1,3 mil exames, com 74 resultados positivos (5,69%). Já nos dias que antecederam a terceira rodada, os quase 1,5 mil testes registraram 16 contaminações para o vírus (cerca de 1%). Clubes como o CSA, na Série B, e o Imperatriz, na Série C, tiveram partidas adiadas devido a casos acumulados no elenco. Os alagoanos chegaram a ter 20 atletas afastados com covid-19. Os maranhenses, 14.
“O número [de infectados] não surpreendeu porque a prevalência espelha, mais ou menos, o que acontece no país. O que nos surpreendeu é que mais de 50% desses casos positivos vieram de cinco clubes”, diz o médico da CBF.
“Os clubes vão se adaptando, os jogadores entendendo melhor esse momento, que afeta a todos. Hoje, os atletas são testados quase duas vezes por semana. A logística atual de realização dos testes, que é descentralizada, facilita muito o controle e evita que partidas sejam canceladas e uma série de transtornos, que podem acontecer. Porém, achamos que, com a revisão dos protocolos, isso será ajustado com o tempo”, sustenta o consultor científico da Sociedade Brasileira de Infectologia (SBI), Carlos Starling.
Os próximos torneios a serem abarcados pelo protocolo são as séries D masculina, que inicia em setembro, e a A2 feminina, que recomeça em outubro. As competições seguirão as diretrizes atuais, mas, devido à realidade das divisões, que reúnem times de menor estrutura e condições financeiras, algumas adaptações podem ser feitas. “Eventualmente, a pesquisa de antígeno viral ou os exames do tipo Lamp [coleta pela saliva] podem ser opções. Estamos avaliando e ajustando o protocolo de acordo com a caraterística das equipes, sem diminuir em nada o grau de segurança”, diz Starling.

Modelo próprio

O protocolo da CBF não é exatamente unânime. No último dia 11, o Sindicato dos Atletas de São Paulo (Sapesp) enviou ofício à entidade pedindo mudanças, ameaçando entrar com ação e paralisar os campeonatos. À Agência Brasil, o presidente do sindicato, Rinaldo Martorelli, citou como exemplos que, a seu ver, poderiam ser adaptados à realidade brasileira, o Campeonato Alemão, com isolamento das delegações por até sete dias antes de cada partida, e a NBA, liga de basquete norte-americana, que reuniu atletas e comissões técnicas em uma bolha na Disney, para término da temporada.
Os médicos ouvidos pela Agência Brasil veem dificuldade de aplicação dos modelos por aqui. “Cada time [de futebol] tem, pelo menos, 42 pessoas escaladas [para um jogo]. Viagens, como faz? Não tem como não isolar o jogador, ele irá ao aeroporto, pegará voo, encontrará outras pessoas. No estádio, há muito mais pessoas envolvidas. Para um estádio funcionar, precisa de umas 100 pessoas. E a gente está falando de um campeonato que vai até março”, pondera Einsfeld, da São Camilo. “Não valeria a pena do ponto de vista financeiro e mental, e não traria qualquer diferença ou benefício, dado que a gente está fazendo a testagem de todo mundo com segurança antes do jogo”, completa.
Starling, da SBI, pensa de forma semelhante. “Temos que achar nosso próprio modelo de retorno, ou tentativa de retorno a uma normalidade. Acho, sim, que a experiência que tem sido desenvolvida aqui pode servir para inúmeros outros países e continentes, como o africano ou o asiático. O registro epidemiológico, as análises estatísticas e o segmento das análises genéticas virais vão gerar uma série de trabalhos científicos para um case nacional. É a expectativa que temos”, conclui.
O post Médico da CBF diz que protocolo do futebol pode ter mudanças apareceu primeiro em Futebol Stats.
from Futebol Stats https://bit.ly/3b0hSF0
via IFTTT
submitted by futebolstats to SiteFutebolStats [link] [comments]


2020.05.25 02:16 roro-xpostbot u/Outhouse_Decorator: COVID-19 Info Page - Updates

Salut din nou /Romania!
A trecut ceva timp de la post-ul initial ( https://old.reddit.com/Romania/comments/fw4etcovid19_info_page/ ) , ceea ce inseamna ca multe articole si rezultate au fost publicate intre timp. Am adaugat majoritatea acestora in tabelul din Info page ( http://moitessier-group.mcgill.ca/covid19/covid.php ) dar m-am gandit ca poate ar fi util sa fac un scurt rezumat al celor mai importate stiri:

Medicamente

  1. Trei medicamente au primit din partea Food and Drug Administration (FDA) autorizatie pentru a fi oferite pacientilor cu COVID-19: hydroxychloroquine/chloroquine, remdesivir si un medicament pentru a seda pacientii ce necesita ventilatie mecanica
  2. Intr-un articol publicat acum 2 zile in publicatia The Lancet ( https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext31180-6/fulltext) ) , un studiu pe 96000 de pacienti arata ca tratamentul cu hydroxychloroquine/chloroquine nu aduce absolut niciun beneficiu pacientilor cu COVID-19. Mai mult, efecte secundare extrem de periculoase (in special aritmii) au fost observate la majoritatea pacientilor.
  3. Intr-un articol publicat acum 2 zile in publicatia The New England Journal of Medicine ( https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 ) rezultatele arata ca remdesivir e superior fata de placebo cand vine vorba de de a petrece mai putine zile in spital (11 fata de 15). In plus, mortalitatea masurata la 14 zile dupa administrarea tratamentului (sau a unui placebo) arata ca pacientii ce au primit remdesivir mor in medie cu 4% mai putin. Foarte important: remdesivir e util DOAR daca e administrat la pacientii cu varianta usoara/medie de COVID-19. Pacientii cu stadii avansate de COVID-19 nu beneficiaza de rezultatele aratate de remdesivir in pacientii cu boala usoara/medie. Principalul motiv este reprezentat de impactul virusului asupra organismului si a replicarii foarte rapide a virusului in acest stadiu.
  4. Multe alte medicamente: ivermectin, lopinaviritonavir, baricitinib, famotidine, favipiravir - se afla in diferite stadii ale studiilor clinice. Rezultate preliminare sunt asteptate in urmatoarele 2-3 luni.

Vaccinuri

Sunt peste 100 de vaccinuri in dezvoltare. Cele mai importante sunt cum urmeaza:
  1. mRNA-1273 dezvoltat de Moderna Therapeutics: faza I a studiilor clinice arata ca anticorpi au fost generati in toti pacientii (45 pacienti sanatosi intre 18-55 ani) carora le a fost administrat vaccinul. Mai mult, rezultatele arata ca vaccinul este tolerat excelent de pacienti, cu efecte secundare minore. Motive de ingrijorare: mai multi cercetatori, in frunte cu John Rose (Yale University) si Anna Durbin (Johns Hopkins University) sunt sceptici cu privire la rezultatele prezentate de Moderna, in special pentru ca rezultatele nu au fost publicate intr-un jurnal peer-reviewed iar metodele nu au fost publicate nicaieri.
  2. ChAdOx1 nCoV-19 dezvoltat de Universitatea Oxford in parteneriat cu AstraZeneca: rezultatele studiilor clinice initiale arata ca vaccinul a protejat 6 maimute de SARS-CoV-2. Faza I a studiilor clinice a fost finalizata pentru peste 1000 de pacienti, cu rezultatele preliminare aflate in curs de publicare. Fazele II si III sunt in prezent in proces de recrutare de participanti.
  3. INO-4800 dezvoltat de Inovio Pharmaceuticals: faza I a studiilor clinice este in desfasurare. 40 de pacienti au primit prima doza iar rezultatele preliminare sunt asteptate in iunie. O data ce rezultatele sunt procesate si (daca sunt) incurajatoare fazele II/III vor incepe in aceasta vara.
Legat de vaccinuri: consensul este ca un vaccin va fi disponibil abia in urmatoarele 12-18 luni (in cel mai optimist caz):
Dr. Emily Erbelding, an infectious disease expert at NIAID -- which is part of the National Institutes of Health -- said the typical vaccine takes between eight and 10 years to develop. While she is careful not to contradict her boss's timeline -- although she did say "18 months would be about as fast as I think we can go" -- she acknowledged that the accelerated pace will involve "not looking at all the data." - https://www.cnn.com/2020/03/31/us/coronavirus-vaccine-timetable-concerns-experts-invs/index.html
Principalul motiv este legat de necesitatea de a urmari raspunsul imun pe o perioada indelungata, pentru a fi siguri ca nu exista efecte adverse. Cel mai probabil un medicament va ajunge pe piata mai repede decat un vaccin, dar deocamdata, pentru a cita un clasic in viata, "urmaresc cu ingrijorare" situatia :)
Pentru a fi la curent cu ce se intampla in cercetare, recomand cu caldura : https://www.nature.com/articles/d41586-020-00502-w ( Nature wades through the literature on the new coronavirus — and summarizes key papers as they appear. )
In incheiere, va doresc tuturor o saptamana placuta si fara evenimente neprevazute!
submitted by roro-xpostbot to omania [link] [comments]


2020.05.24 19:24 Outhouse_Decorator COVID-19 Info Page - Updates

Salut din nou /Romania!
A trecut ceva timp de la post-ul initial ( https://old.reddit.com/Romania/comments/fw4etcovid19_info_page/ ) , ceea ce inseamna ca multe articole si rezultate au fost publicate intre timp. Am adaugat majoritatea acestora in tabelul din Info page ( http://moitessier-group.mcgill.ca/covid19/covid.php ) dar m-am gandit ca poate ar fi util sa fac un scurt rezumat al celor mai importate stiri:

Medicamente

  1. Trei medicamente au primit din partea Food and Drug Administration (FDA) autorizatie pentru a fi oferite pacientilor cu COVID-19: hydroxychloroquine/chloroquine, remdesivir si un medicament pentru a seda pacientii ce necesita ventilatie mecanica
  2. Intr-un articol publicat acum 2 zile in publicatia The Lancet ( https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext31180-6/fulltext) ) , un studiu pe 96000 de pacienti arata ca tratamentul cu hydroxychloroquine/chloroquine nu aduce absolut niciun beneficiu pacientilor cu COVID-19. Mai mult, efecte secundare extrem de periculoase (in special aritmii) au fost observate la majoritatea pacientilor.
  3. Intr-un articol publicat acum 2 zile in publicatia The New England Journal of Medicine ( https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 ) rezultatele arata ca remdesivir e superior fata de placebo cand vine vorba de de a petrece mai putine zile in spital (11 fata de 15). In plus, mortalitatea masurata la 14 zile dupa administrarea tratamentului (sau a unui placebo) arata ca pacientii ce au primit remdesivir mor in medie cu 4.8 puncte procentuale mai putin. Foarte important: remdesivir e util DOAR daca e administrat la pacientii cu varianta usoara/medie de COVID-19. Pacientii cu stadii avansate de COVID-19 nu beneficiaza de rezultatele aratate de remdesivir in pacientii cu boala usoara/medie. Principalul motiv este reprezentat de impactul virusului asupra organismului si a replicarii foarte rapide a virusului in acest stadiu.
  4. Multe alte medicamente: ivermectin, lopinaviritonavir, baricitinib, famotidine, favipiravir - se afla in diferite stadii ale studiilor clinice. Rezultate preliminare sunt asteptate in urmatoarele 2-3 luni.

Vaccinuri

Sunt peste 100 de vaccinuri in dezvoltare. Cele mai importante sunt cum urmeaza:
  1. mRNA-1273 dezvoltat de Moderna Therapeutics: faza I a studiilor clinice arata ca anticorpi au fost generati in toti pacientii (45 pacienti sanatosi intre 18-55 ani) carora le a fost administrat vaccinul. Mai mult, rezultatele arata ca vaccinul este tolerat excelent de pacienti, cu efecte secundare minore. Motive de ingrijorare: mai multi cercetatori, in frunte cu John Rose (Yale University) si Anna Durbin (Johns Hopkins University) sunt sceptici cu privire la rezultatele prezentate de Moderna, in special pentru ca rezultatele nu au fost publicate intr-un jurnal peer-reviewed iar metodele nu au fost publicate nicaieri.
  2. ChAdOx1 nCoV-19 dezvoltat de Universitatea Oxford in parteneriat cu AstraZeneca: rezultatele studiilor clinice initiale arata ca vaccinul a protejat 6 maimute de SARS-CoV-2. Faza I a studiilor clinice a fost finalizata pentru peste 1000 de pacienti, cu rezultatele preliminare aflate in curs de publicare. Fazele II si III sunt in prezent in proces de recrutare de participanti.
  3. INO-4800 dezvoltat de Inovio Pharmaceuticals: faza I a studiilor clinice este in desfasurare. 40 de pacienti au primit prima doza iar rezultatele preliminare sunt asteptate in iunie. O data ce rezultatele sunt procesate si (daca sunt) incurajatoare fazele II/III vor incepe in aceasta vara.
Legat de vaccinuri: consensul este ca un vaccin va fi disponibil abia in urmatoarele 12-18 luni (in cel mai optimist caz):
Dr. Emily Erbelding, an infectious disease expert at NIAID -- which is part of the National Institutes of Health -- said the typical vaccine takes between eight and 10 years to develop. While she is careful not to contradict her boss's timeline -- although she did say "18 months would be about as fast as I think we can go" -- she acknowledged that the accelerated pace will involve "not looking at all the data." - https://www.cnn.com/2020/03/31/us/coronavirus-vaccine-timetable-concerns-experts-invs/index.html
Principalul motiv este legat de necesitatea de a urmari raspunsul imun pe o perioada indelungata, pentru a fi siguri ca nu exista efecte adverse. Cel mai probabil un medicament va ajunge pe piata mai repede decat un vaccin, dar deocamdata, pentru a cita un clasic in viata, "urmaresc cu ingrijorare" situatia :)
Pentru a fi la curent cu ce se intampla in cercetare, recomand cu caldura : https://www.nature.com/articles/d41586-020-00502-w ( Nature wades through the literature on the new coronavirus — and summarizes key papers as they appear. )
In incheiere, va doresc tuturor o saptamana placuta si fara evenimente neprevazute!
submitted by Outhouse_Decorator to Romania [link] [comments]


2020.02.20 19:44 Quippykisset dr4

https://app.dealroom.co/investors/phystech\_ventures
https://app.dealroom.co/companies/qiwi
https://app.dealroom.co/investors/martin\_mccourt
https://app.dealroom.co/companies/semtech
https://app.dealroom.co/investors/michael\_moritz\_1
https://app.dealroom.co/investors/boyser\_srl
https://app.dealroom.co/investors/carlo\_k\_lzer
https://app.dealroom.co/investors/andre\_bajorat
https://app.dealroom.co/investors/mistletoe
https://app.dealroom.co/investors/gert\_nordin
https://app.dealroom.co/investors/enfuro\_ventures
https://app.dealroom.co/investors/breton\_fund
https://app.dealroom.co/investors/savoie\_mont\_blanc\_angels
https://app.dealroom.co/investors/swiss\_ict\_investor\_club\_sictic\_
https://app.dealroom.co/investors/clearly\_social\_angels
https://app.dealroom.co/investors/angels\_sante
https://app.dealroom.co/companies/gdtre
https://app.dealroom.co/investors/third\_rock\_ventures
https://app.dealroom.co/investors/casdin\_capital
https://app.dealroom.co/investors/heritage\_provider\_network
https://app.dealroom.co/investors/steve\_parish
https://app.dealroom.co/investors/airbridge\_equity\_partners
https://app.dealroom.co/investors/admitad\_invest
https://app.dealroom.co/investors/humanity\_united
https://app.dealroom.co/investors/christian\_kaar\_1
https://app.dealroom.co/investors/rene\_giretzlehner
https://app.dealroom.co/investors/alfred\_luger
https://app.dealroom.co/investors/florian\_gschwandtner
https://app.dealroom.co/investors/dieter\_von\_holtzbrinck
https://app.dealroom.co/investors/jazz\_venture\_partners
https://app.dealroom.co/companies/\_ez
https://app.dealroom.co/investors/idea\_
https://app.dealroom.co/investors/ntt\_docomo\_ventures
https://app.dealroom.co/investors/long\_arc\_capital
https://app.dealroom.co/investors/at\_impf\_gmbh
https://app.dealroom.co/investors/iseed\_ventures
https://app.dealroom.co/investors/andrew\_weisz
https://app.dealroom.co/companies/tandem\_1
https://app.dealroom.co/investors/nick\_kingsbury
https://app.dealroom.co/investors/committed\_capital\_limited
https://app.dealroom.co/companies/edenred
https://app.dealroom.co/companies/global\_telecom\_technology\_gtt
https://app.dealroom.co/investors/cormorant\_asset\_management
https://app.dealroom.co/investors/emh\_partners
https://app.dealroom.co/investors/sirona\_capital
https://app.dealroom.co/companies/gilead
https://app.dealroom.co/investors/limburg\_ventures
https://app.dealroom.co/investors/adour\_business\_angels
https://app.dealroom.co/investors/western\_digital\_capital
https://app.dealroom.co/investors/scientipole\_ile\_de\_france\_capital
https://app.dealroom.co/investors/tommy\_andersen
https://app.dealroom.co/investors/saastr\_fund
https://app.dealroom.co/investors/digital\_future
https://app.dealroom.co/companies/wefunder
https://app.dealroom.co/investors/alan\_morgan
https://app.dealroom.co/investors/paul\_topley
https://app.dealroom.co/companies/lombard\_odier
https://app.dealroom.co/companies/level\_equity
https://app.dealroom.co/investors/eiffel\_investment\_group
https://app.dealroom.co/investors/signal\_peak\_ventures
https://app.dealroom.co/investors/stephan\_schambach
https://app.dealroom.co/investors/paca\_emergence
https://app.dealroom.co/investors/dima\_ventures
https://app.dealroom.co/investors/aqua\_spark
https://app.dealroom.co/investors/sycamore\_partners
https://app.dealroom.co/investors/longwood\_founders\_fund
https://app.dealroom.co/investors/verizon\_ventures
https://app.dealroom.co/investors/power\_financial\_corporation
https://app.dealroom.co/investors/future\_fund
https://app.dealroom.co/investors/karl\_magnus\_troedsson
https://app.dealroom.co/investors/ag2r\_la\_mondiale
https://app.dealroom.co/investors/intesa\_sanpaolo
https://app.dealroom.co/investors/cleantech\_invest
https://app.dealroom.co/companies/oxford\_technology\_management
https://app.dealroom.co/companies/e\_on
https://app.dealroom.co/investors/the\_riverside\_company
https://app.dealroom.co/companies/vasco
https://app.dealroom.co/companies/sig\_plc
https://app.dealroom.co/companies/storytel\_ab
https://app.dealroom.co/companies/hexagon\_ab
https://app.dealroom.co/investors/aac\_capital\_partners
https://app.dealroom.co/investors/jean\_charles\_samuelian
https://app.dealroom.co/investors/harwell\_capital
https://app.dealroom.co/investors/draper\_nexus
https://app.dealroom.co/investors/audi\_electronics\_venture
https://app.dealroom.co/investors/space\_angels
https://app.dealroom.co/companies/valid\_com
https://app.dealroom.co/investors/bamboo\_capital
https://app.dealroom.co/investors/be\_angels
https://app.dealroom.co/investors/simon\_nixon
https://app.dealroom.co/investors/nick\_hynes
https://app.dealroom.co/investors/erwin\_arkema
https://app.dealroom.co/investors/william\_tunstall\_pedoe
https://app.dealroom.co/investors/5am\_ventures
https://app.dealroom.co/investors/lanta\_digital\_ventures
https://app.dealroom.co/investors/bernard\_arnault
https://app.dealroom.co/companies/leaseplan
https://app.dealroom.co/investors/s\_cubed
https://app.dealroom.co/investors/june\_fund
https://app.dealroom.co/investors/xfund
https://app.dealroom.co/investors/andy\_chung
https://app.dealroom.co/investors/matthew\_bellamy
https://app.dealroom.co/companies/power\_corporation\_of\_canada
https://app.dealroom.co/investors/sumeru\_equity\_partners
https://app.dealroom.co/investors/francois\_enaud
https://app.dealroom.co/investors/diffusion\_capital\_partners
https://app.dealroom.co/investors/stella\_maris\_partners
https://app.dealroom.co/investors/autotech\_ventures
https://app.dealroom.co/investors/fraser\_mccombs\_capital
https://app.dealroom.co/investors/singtel\_innov8
https://app.dealroom.co/companies/virgin\_group
https://app.dealroom.co/investors/prudence\_holdings
https://app.dealroom.co/investors/nokota\_management
https://app.dealroom.co/investors/armat\_group
https://app.dealroom.co/investors/marshfield\_associates
https://app.dealroom.co/investors/silver\_lake\_kraftwerk
https://app.dealroom.co/companies/alfahim
https://app.dealroom.co/companies/thales\_group
https://app.dealroom.co/companies/jpmorgan\_chase
https://app.dealroom.co/investors/sverdlovsk\_venture\_fund
https://app.dealroom.co/investors/neo\_investment\_partners
https://app.dealroom.co/investors/arrowgrass
https://app.dealroom.co/companies/htc
https://app.dealroom.co/companies/nestl\_health\_science
https://app.dealroom.co/investors/health\_for\_life\_capital
https://app.dealroom.co/investors/moira\_capital\_partners
https://app.dealroom.co/companies/bristol\_myers\_squibb
https://app.dealroom.co/companies/bank\_of\_china
https://app.dealroom.co/investors/lyfe\_capital
https://app.dealroom.co/companies/fort\_knox\_f\_rvaring
https://app.dealroom.co/investors/enso\_ventures\_1
https://app.dealroom.co/companies/lsl\_property\_services
https://app.dealroom.co/investors/bundeep\_singh\_rangar
https://app.dealroom.co/investors/rubicon\_vc
https://app.dealroom.co/investors/braemar\_energy\_ventures
https://app.dealroom.co/investors/thomvest\_ventures
https://app.dealroom.co/investors/david\_rowan
https://app.dealroom.co/investors/quadrille\_capital
https://app.dealroom.co/investors/victor\_amp\_victor
https://app.dealroom.co/investors/daniel\_pilotti
https://app.dealroom.co/investors/troy\_collins
https://app.dealroom.co/investors/julien\_codorniou\_1
https://app.dealroom.co/investors/sib\_innovations\_und\_beteiligungsgesellschaft\_mbh
https://app.dealroom.co/investors/horizonx
https://app.dealroom.co/investors/ptb\_ventures
https://app.dealroom.co/investors/nightdragon\_security
https://app.dealroom.co/companies/bae\_systems
https://app.dealroom.co/companies/rolls\_royce\_1
https://app.dealroom.co/companies/ventureclub
https://app.dealroom.co/investors/dhs\_venture\_partners
https://app.dealroom.co/companies/china\_camel\_group
https://app.dealroom.co/investors/christopher\_spray
https://app.dealroom.co/investors/alex\_saint
https://app.dealroom.co/investors/sergey\_solonin
https://app.dealroom.co/companies/adesso
https://app.dealroom.co/investors/triton
https://app.dealroom.co/investors/bonventure
https://app.dealroom.co/investors/vector\_venture\_capital
https://app.dealroom.co/investors/hig\_capital
https://app.dealroom.co/companies/syngenta
https://app.dealroom.co/companies/investoo
https://app.dealroom.co/investors/natixis
https://app.dealroom.co/companies/zurich\_insurance\_group
https://app.dealroom.co/investors/scania\_growth\_capital
https://app.dealroom.co/companies/paradox\_interactive
https://app.dealroom.co/investors/isabella\_l\_wengrip
https://app.dealroom.co/companies/stillfront
https://app.dealroom.co/investors/mirach\_capital\_group
https://app.dealroom.co/investors/athanase
https://app.dealroom.co/investors/aleph
https://app.dealroom.co/investors/slow\_ventures
https://app.dealroom.co/investors/ibex\_ventures
https://app.dealroom.co/investors/alychlo
https://app.dealroom.co/companies/nationwide\_insurance
https://app.dealroom.co/investors/svc
https://app.dealroom.co/companies/genextra
https://app.dealroom.co/investors/reinvent
https://app.dealroom.co/investors/next\_world\_capital
https://app.dealroom.co/investors/la\_bolsa\_social
https://app.dealroom.co/investors/fredrik\_wester
https://app.dealroom.co/investors/mehrdad\_piroozram
https://app.dealroom.co/companies/nex\_opportunities
https://app.dealroom.co/investors/club\_invest\_idf
https://app.dealroom.co/investors/middleton\_enterprises
https://app.dealroom.co/investors/some\_random\_vc
https://app.dealroom.co/companies/awin
https://app.dealroom.co/investors/ming\_capital
https://app.dealroom.co/investors/careventures
https://app.dealroom.co/investors/swiss\_priv\_e
https://app.dealroom.co/companies/psn
https://app.dealroom.co/investors/all\_iron\_ventures
https://app.dealroom.co/investors/thomas\_hoegh
https://app.dealroom.co/investors/clive\_cowdery
https://app.dealroom.co/companies/recruit\_holdings
https://app.dealroom.co/companies/zynga
https://app.dealroom.co/investors/laurent\_dassault
https://app.dealroom.co/investors/jadeberg\_partners
https://app.dealroom.co/investors/red\_sea\_ventures
https://app.dealroom.co/companies/siemens\_technology\_accelerator
https://app.dealroom.co/investors/courtin\_investment
https://app.dealroom.co/investors/sos\_ventures
https://app.dealroom.co/companies/zendesk
https://app.dealroom.co/companies/jobcloud
https://app.dealroom.co/companies/at\_t
https://app.dealroom.co/investors/marius\_nacht
https://app.dealroom.co/investors/california\_technology\_ventures
https://app.dealroom.co/companies/clas\_ohlson
https://app.dealroom.co/companies/ulule
https://app.dealroom.co/investors/turn8
https://app.dealroom.co/investors/escalate\_capital\_partners
https://app.dealroom.co/investors/pengpai
https://app.dealroom.co/investors/eurekap\_
https://app.dealroom.co/investors/helea\_financiere
https://app.dealroom.co/companies/nws\_holdings
https://app.dealroom.co/investors/venrock
https://app.dealroom.co/companies/elior\_group
https://app.dealroom.co/investors/sts\_ventures
https://app.dealroom.co/investors/alsace\_business\_angels
https://app.dealroom.co/investors/boost\_vc
https://app.dealroom.co/investors/tandem\_capital
https://app.dealroom.co/investors/bourgogne\_angels
https://app.dealroom.co/investors/evonik\_venture\_capital\_gmbh
https://app.dealroom.co/companies/rostelecom
https://app.dealroom.co/companies/telenet\_holding
https://app.dealroom.co/companies/mairdumont
https://app.dealroom.co/companies/here
https://app.dealroom.co/companies/bestseller
https://app.dealroom.co/companies/secret\_escapes
https://app.dealroom.co/companies/sony
https://app.dealroom.co/investors/polaris\_private\_equity
https://app.dealroom.co/companies/blablacar
https://app.dealroom.co/companies/trimble
https://app.dealroom.co/companies/adidas
https://app.dealroom.co/companies/atlas\_copco
https://app.dealroom.co/companies/bmw\_group
https://app.dealroom.co/investors/npm\_capital
https://app.dealroom.co/investors/parcom\_capital
https://app.dealroom.co/investors/mentha\_capital
https://app.dealroom.co/investors/nom
https://app.dealroom.co/companies/starbreeze\_studios
https://app.dealroom.co/investors/ban\_vlaanderen
https://app.dealroom.co/investors/mark\_pincus
https://app.dealroom.co/investors/rikard\_steiber
https://app.dealroom.co/investors/mons\_investments
https://app.dealroom.co/investors/sundt\_as
https://app.dealroom.co/investors/stokke\_industri
https://app.dealroom.co/investors/str\_mstangen
https://app.dealroom.co/investors/arctic\_fund\_management
https://app.dealroom.co/companies/startx
https://app.dealroom.co/investors/samir\_desai
https://app.dealroom.co/investors/\_stersj\_stiftelsen
https://app.dealroom.co/companies/fonterra\_co\_operative\_group
https://app.dealroom.co/investors/big\_ban\_angels
https://app.dealroom.co/investors/evoco
https://app.dealroom.co/investors/headway\_capital\_partners
https://app.dealroom.co/investors/keyhaven\_capital\_partners
https://app.dealroom.co/investors/future\_planet\_capital
https://app.dealroom.co/companies/nanogate
https://app.dealroom.co/companies/plastic\_omnium
https://app.dealroom.co/investors/christophe\_chausson
https://app.dealroom.co/investors/anton\_antich
https://app.dealroom.co/investors/elevator
https://app.dealroom.co/investors/praetura\_capital\_llp
https://app.dealroom.co/investors/apadmi\_ventures
https://app.dealroom.co/investors/groupe\_paul\_bocuse
https://app.dealroom.co/investors/i2bf\_global\_ventures
https://app.dealroom.co/investors/signalfire
https://app.dealroom.co/investors/j\_p\_morgan
https://app.dealroom.co/companies/avast\_software\_a\_s
https://app.dealroom.co/companies/cellcom\_israel
https://app.dealroom.co/companies/fiege\_logistics
https://app.dealroom.co/investors/james\_mullen
https://app.dealroom.co/investors/nano\_future\_invest
https://app.dealroom.co/investors/mayfair\_equity\_partners
https://app.dealroom.co/investors/amplo
https://app.dealroom.co/investors/icebreaker\_vc
https://app.dealroom.co/investors/sham
https://app.dealroom.co/investors/european\_life\_sciences\_growth\_fund
https://app.dealroom.co/investors/cathay\_ventures
https://app.dealroom.co/investors/pivotal\_bioventures\_partners
https://app.dealroom.co/investors/bay\_city\_capital
https://app.dealroom.co/investors/mi\_care\_s\_a\_
https://app.dealroom.co/investors/sham\_innovation\_sant\_turenne
https://app.dealroom.co/investors/sofipaca
https://app.dealroom.co/companies/silfurberg
https://app.dealroom.co/investors/giuseppe\_donagemma\_1
https://app.dealroom.co/investors/jonathan\_weiner
https://app.dealroom.co/investors/ray\_iglesias\_iii
https://app.dealroom.co/investors/nicolas\_carbonari
https://app.dealroom.co/investors/christophe\_navarre
https://app.dealroom.co/investors/tom\_valentine
https://app.dealroom.co/investors/scp\_neptune\_international
https://app.dealroom.co/investors/red\_circle\_investment
https://app.dealroom.co/investors/vivo\_capital
https://app.dealroom.co/investors/rakuten\_capital
https://app.dealroom.co/investors/gr\_capital
https://app.dealroom.co/investors/7percent
https://app.dealroom.co/investors/8vc
https://app.dealroom.co/investors/tom\_valentine
https://app.dealroom.co/investors/skagen
https://app.dealroom.co/investors/shasta\_ventures
https://app.dealroom.co/investors/jne\_invest
https://app.dealroom.co/investors/jordi\_ber
https://app.dealroom.co/investors/walerud\_ventures
https://app.dealroom.co/investors/demetrios\_zoppos
https://app.dealroom.co/investors/true\_
https://app.dealroom.co/investors/cita\_investissement
https://app.dealroom.co/investors/seed4soft
https://app.dealroom.co/investors/hessen\_kapital
https://app.dealroom.co/companies/maxhealth\_medicine\_group
https://app.dealroom.co/investors/peter\_brabeck\_letmathe
https://app.dealroom.co/investors/arkady\_volozh
https://app.dealroom.co/investors/pierangelo\_bottinelli
https://app.dealroom.co/investors/philippe\_glatz
https://app.dealroom.co/investors/jean\_bernard\_1
https://app.dealroom.co/investors/nelson\_dumas
https://app.dealroom.co/investors/magnus\_emilson
https://app.dealroom.co/investors/tony\_fadell
https://app.dealroom.co/investors/romain\_afflelou
https://app.dealroom.co/investors/cl\_ment\_benoit\_1
https://app.dealroom.co/investors/cultivian\_sandbox\_ventures
https://app.dealroom.co/investors/global\_health\_science\_fund
https://app.dealroom.co/companies/ferrer
https://app.dealroom.co/companies/deutsche\_telemedien
https://app.dealroom.co/investors/andrew\_black
https://app.dealroom.co/investors/henderson\_ventures
https://app.dealroom.co/investors/vintage\_investment\_partners
https://app.dealroom.co/investors/qumra\_capital
https://app.dealroom.co/investors/peter\_sands
https://app.dealroom.co/investors/eilert\_hanoa
https://app.dealroom.co/investors/the\_kairo\_society
https://app.dealroom.co/investors/guinness\_asset\_management
https://app.dealroom.co/investors/foundation\_fighting\_blindness\_clinical\_research\_institute\_ffb\_cri\_
https://app.dealroom.co/investors/see\_amp\_entender\_foundation\_fve\_
https://app.dealroom.co/investors/andrew\_mullinger
https://app.dealroom.co/investors/impact\_ventures\_llp
https://app.dealroom.co/investors/lanai\_partners
https://app.dealroom.co/investors/bullpen\_capital
https://app.dealroom.co/investors/ird\_group
https://app.dealroom.co/investors/deca\_investments
https://app.dealroom.co/investors/undi\_private\_equity
https://app.dealroom.co/investors/vgo\_ventures
https://app.dealroom.co/investors/cemag\_invest
https://app.dealroom.co/investors/black\_toro\_capital
https://app.dealroom.co/companies/kmre\_group
https://app.dealroom.co/investors/nami\_zarringhalam
https://app.dealroom.co/companies/sygnature\_discovery
https://app.dealroom.co/companies/imagine\_institute
https://app.dealroom.co/investors/cme\_ventures
https://app.dealroom.co/investors/gobi\_partners
https://app.dealroom.co/investors/date\_invest
https://app.dealroom.co/investors/tiin\_techfund\_3
https://app.dealroom.co/investors/bertrand\_diard\_1
https://app.dealroom.co/investors/transdev
https://app.dealroom.co/investors/denso\_ventures
https://app.dealroom.co/investors/veho\_fi
https://app.dealroom.co/companies/aioi\_nissay\_dowa
https://app.dealroom.co/companies/karsan
https://app.dealroom.co/companies/swiftcom
https://app.dealroom.co/companies/nordnet\_bank\_ab
https://app.dealroom.co/investors/pontos\_group
https://app.dealroom.co/investors/jaakko\_ollila
https://app.dealroom.co/investors/julien\_leroy
https://app.dealroom.co/companies/agfa\_healthcare\_e\_s
https://app.dealroom.co/investors/dnb\_norway
https://app.dealroom.co/investors/rainer\_marc\_frey
https://app.dealroom.co/investors/philipp\_cottier
https://app.dealroom.co/investors/javier\_etxebeste
https://app.dealroom.co/investors/investor\_growth\_capital
https://app.dealroom.co/investors/dsg\_consumer\_partners
https://app.dealroom.co/investors/onset\_ventures
https://app.dealroom.co/investors/mexico\_ventures
https://app.dealroom.co/investors/morningside\_venture\_capital
https://app.dealroom.co/investors/droia\_oncology\_ventures
https://app.dealroom.co/investors/gate\_93
https://app.dealroom.co/investors/modara\_technologies
https://app.dealroom.co/investors/gaw\_capital
https://app.dealroom.co/companies/sansiri
https://app.dealroom.co/companies/bkk
https://app.dealroom.co/investors/banco\_bni\_europa
https://app.dealroom.co/investors/juli\_n\_l\_pez\_zaballos
https://app.dealroom.co/investors/pontus\_jansson
https://app.dealroom.co/investors/robin\_olsen
https://app.dealroom.co/investors/compound
https://app.dealroom.co/investors/female\_founders\_fund
https://app.dealroom.co/investors/b\_y\_venture\_partners
https://app.dealroom.co/investors/french\_partners
https://app.dealroom.co/investors/tord\_wingren
https://app.dealroom.co/investors/bigbang\_angels
https://app.dealroom.co/investors/extens
https://app.dealroom.co/companies/ethereum
https://app.dealroom.co/investors/pamela\_patsley
https://app.dealroom.co/investors/finparx
https://app.dealroom.co/companies/oddo\_cie
https://app.dealroom.co/investors/venrex\_investment\_management
https://app.dealroom.co/investors/georg\_b\_rtlein
https://app.dealroom.co/investors/softbank\_ventures\_korea
https://app.dealroom.co/investors/livanova
https://app.dealroom.co/investors/peakspan\_capital
submitted by Quippykisset to peaceCorpsCoding [link] [comments]


Talk About Your Daily Routine in English - Spoken English ... Frases célebres de Margaret Thatcher 5 Historias de citas a ciegas │ MundoCreepy │ NightCrawler ... Citas Consulares - YouTube Como hacer citas en un texto - YouTube app de citas 1/5 - YouTube Estafas de citas por internet - YouTube Airport English - At the Airport - Spoken English Lesson ... Insertar tabla de contenidos y citas word SISTEMA DE CITAS EN EXCEL GRATIS - YouTube

Citas En Oxford Msds - intereses prestamos personales ing

  1. Talk About Your Daily Routine in English - Spoken English ...
  2. Frases célebres de Margaret Thatcher
  3. 5 Historias de citas a ciegas │ MundoCreepy │ NightCrawler ...
  4. Citas Consulares - YouTube
  5. Como hacer citas en un texto - YouTube
  6. app de citas 1/5 - YouTube
  7. Estafas de citas por internet - YouTube
  8. Airport English - At the Airport - Spoken English Lesson ...
  9. Insertar tabla de contenidos y citas word
  10. SISTEMA DE CITAS EN EXCEL GRATIS - YouTube

Este vídeo es una Re-Edición de el originalmente subido el año pasado con el fin de hacerlo apto para todo el publico y para anunciantes. ¡SUSCRIBETE! http... Inserta automáticamente una tabla de contenido, referencias y biografía en Word. Guía para la realizar citas dentro de un texto siguiendo el formato APA-- Created using PowToon -- Free sign up at http://www.powtoon.com/ . Make your own an... Impostores que les prometen relaciones amorosas a los usuarios de sitios de citas por internet para engañarlos para que les envíen dinero. This lesson will give you useful airport English words and phrases you can use at the airport. Remember to share your airport or plane experiences in the com... In this lesson, you’ll learn how to talk about your daily routine in English.What do you do every day? What’s a typical day like for you? In this class, you’... Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube. hola mis pequeños Fujoshi y fandashis pervertidos hoy les traigo la primera parte de app de citas Política británica, primera ministra de 1979 a 1990. Margaret Hilda Roberts estudió ciencias químicas en la Universidad de Oxford y trabajó cuatro años como investigadora química. En 1951 ... LINK DE DESCARGA: http://www.mediafire.com/file/3tsfh6vu4cz3o35/SISTEMA_DE_CITAS.xlsm/file